282 related articles for article (PubMed ID: 22417924)
1. Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.
Martin HL; Mounsey RB; Mustafa S; Sathe K; Teismann P
Exp Neurol; 2012 Jun; 235(2):528-38. PubMed ID: 22417924
[TBL] [Abstract][Full Text] [Related]
2. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.
Yi JH; Park SW; Brooks N; Lang BT; Vemuganti R
Brain Res; 2008 Dec; 1244():164-72. PubMed ID: 18948087
[TBL] [Abstract][Full Text] [Related]
3. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Garrido-Gil P; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
J Neuroinflammation; 2012 Feb; 9():38. PubMed ID: 22356806
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
7. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Quinn LP; Crook B; Hows ME; Vidgeon-Hart M; Chapman H; Upton N; Medhurst AD; Virley DJ
Br J Pharmacol; 2008 May; 154(1):226-33. PubMed ID: 18332857
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Lecca D; Nevin DK; Mulas G; Casu MA; Diana A; Rossi D; Sacchetti G; Fayne D; Carta AR
Neuroscience; 2015 Aug; 302():23-35. PubMed ID: 25907448
[TBL] [Abstract][Full Text] [Related]
10. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
11. Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.
Zeissler ML; Eastwood J; McCorry K; Hanemann CO; Zajicek JP; Carroll CB
Oncotarget; 2016 Jul; 7(29):46603-46614. PubMed ID: 27366949
[TBL] [Abstract][Full Text] [Related]
12. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.
He H; Tao H; Xiong H; Duan SZ; McGowan FX; Mortensen RM; Balschi JA
Toxicol Sci; 2014 Apr; 138(2):468-81. PubMed ID: 24449420
[TBL] [Abstract][Full Text] [Related]
14. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia.
Zhao X; Strong R; Zhang J; Sun G; Tsien JZ; Cui Z; Grotta JC; Aronowski J
J Neurosci; 2009 May; 29(19):6186-95. PubMed ID: 19439596
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
[TBL] [Abstract][Full Text] [Related]
16. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
Seargent JM; Yates EA; Gill JH
Br J Pharmacol; 2004 Dec; 143(8):933-7. PubMed ID: 15533890
[TBL] [Abstract][Full Text] [Related]
17. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
18. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus.
Yu X; Shao XG; Sun H; Li YN; Yang J; Deng YC; Huang YG
Brain Res; 2008 Mar; 1200():146-58. PubMed ID: 18289512
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model.
Lee Y; Cho JH; Lee S; Lee W; Chang SC; Chung HY; Moon HR; Lee J
Brain Res; 2019 Feb; 1704():47-58. PubMed ID: 30273550
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
